Nascent Biotech Financials
| NBIO Stock | USD 0.05 0.0004 0.73% |
With this module, you can analyze Nascent financials for your investing period. You should be able to track the changes in Nascent Biotech individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.
Nascent |
The data published in Nascent Biotech's official financial statements typically reflect Nascent Biotech's business processes, product offerings, services, and other fundamental events. However, there are additional fundamental indicators that are easier to understand and visualize along the underlying realities that are driving Nascent Biotech's quantitative information. For example, before you start analyzing numbers published by Nascent accountants, it's essential to understand Nascent Biotech's liquidity, profitability, and earnings quality within the context of the Healthcare space in which it operates.
Nascent Biotech Stock Summary
Nascent Biotech competes with Silo Pharma, Protagenic Therapeutics, Sino Biopharmaceutica, and Eledon Pharmaceuticals. Nascent Biotech, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. In addition, the company is developing MultiPharm, a proprietary technology platform for cancer therapy, as well as diabetes, autoimmunity, and transplantation. Nascent Biotech operates under Biotechnology classification in the United States and is traded on OTC Exchange.| Instrument | USA OTC Stock View All |
| Exchange | OTCQB Exchange |
| ISIN | US63108Q1013 |
| Business Address | 623 17th Street, |
| Sector | Healthcare |
| Industry | Biotechnology |
| Benchmark | Dow Jones Industrial |
| Website | www.nascentbiotech.com |
| Phone | 612 961 5656 |
| Currency | USD - US Dollar |
Nascent Biotech Key Financial Ratios
Nascent Biotech's financial ratios allow both analysts and investors to convert raw data from Nascent Biotech's financial statements into concise, actionable information that can be used to evaluate the performance of Nascent Biotech over time and compare it to other companies across industries.| Return On Asset | -0.88 | |||
| Beta | -3.14 |
Nascent Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Nascent Biotech's current stock value. Our valuation model uses many indicators to compare Nascent Biotech value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Nascent Biotech competition to find correlations between indicators driving Nascent Biotech's intrinsic value. More Info.Nascent Biotech is considered to be number one stock in return on asset category among its peers. It also is considered to be number one stock in profit margin category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Nascent Biotech by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Nascent Biotech's OTC Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Nascent Biotech Systematic Risk
Nascent Biotech's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Nascent Biotech volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was fourteen with a total number of output elements of fourty-seven. The Beta measures systematic risk based on how returns on Nascent Biotech correlated with the market. If Beta is less than 0 Nascent Biotech generally moves in the opposite direction as compared to the market. If Nascent Biotech Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Nascent Biotech is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Nascent Biotech is generally in the same direction as the market. If Beta > 1 Nascent Biotech moves generally in the same direction as, but more than the movement of the benchmark.
Nascent Biotech December 11, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Nascent Biotech help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Nascent Biotech. We use our internally-developed statistical techniques to arrive at the intrinsic value of Nascent Biotech based on widely used predictive technical indicators. In general, we focus on analyzing Nascent OTC Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Nascent Biotech's daily price indicators and compare them against related drivers.
| Downside Deviation | 11.3 | |||
| Information Ratio | 0.0638 | |||
| Maximum Drawdown | 76.58 | |||
| Value At Risk | (15.82) | |||
| Potential Upside | 21.35 |
Other Information on Investing in Nascent OTC Stock
Nascent Biotech financial ratios help investors to determine whether Nascent OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Nascent with respect to the benefits of owning Nascent Biotech security.